Clene Inc. (NASDAQ: CLNN) has announced its second quarter 2025 financial results while outlining significant progress in its clinical development programs for neurodegenerative diseases. The company confirmed plans to submit a New Drug Application for its lead candidate CNM-Au8® in amyotrophic lateral sclerosis by the end of 2025, marking a critical milestone in the treatment landscape for this devastating condition.
The company has scheduled meetings with the U.S. Food and Drug Administration for the third quarter of 2025 to discuss ALS survival benefit data and multiple sclerosis development plans. These regulatory interactions will help shape the path forward for CNM-Au8, an oral suspension of gold nanocrystals designed to restore neuronal health through improved energy metabolism. The treatment represents a novel approach to addressing mitochondrial dysfunction in neurodegenerative diseases.
Additional data analysis from the NIH-sponsored Expanded Access Program focusing on neurofilament light biomarker changes is expected in early fourth quarter 2025. This biomarker data could provide valuable insights into treatment efficacy and potentially support the regulatory submission process. The company recently held a Type C meeting with the FDA to align on statistical methodology for analyzing these biomarker changes, demonstrating careful attention to regulatory requirements.
Financially, Clene reported $7.3 million in cash and cash equivalents as of June 30, 2025, with recent financing extending the company's cash runway into the first quarter of 2026. This extended financial stability provides the company with sufficient resources to advance its clinical programs through key regulatory milestones. The latest news and updates relating to CLNN are available in the company's newsroom at https://ibn.fm/CLNN.
The progression toward NDA submission represents a significant step for patients suffering from ALS, a condition with limited treatment options and high unmet medical need. Successful development of CNM-Au8 could offer new hope for individuals affected by this progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. For the biotechnology industry, Clene's approach to improving mitochondrial health and protecting neuronal function represents an innovative direction in neurodegenerative disease treatment research.
As the company moves toward its year-end NDA submission target, the upcoming FDA meetings and biomarker data analysis will be critical in determining the regulatory pathway and potential approval timeline. The extended financial runway ensures that Clene can continue its development activities without immediate funding concerns, allowing focused attention on advancing CNM-Au8 through the regulatory process and potentially bringing new treatment options to patients in need.
